Ratings Adocia

Equities

ADOC

FR0011184241

Market Closed - Euronext Paris Other stock markets 11:35:00 2024-04-30 am EDT			5-day change	1st Jan Change
8.36 ^EUR	0.00%		-3.02%	-27.56%

Apr. 24	Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 22	Adocia: announces fund-raising	CF

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.

Weaknesses

The company's enterprise value to sales, at 6.56 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ADOCIA	-27.56%	128M	-
VERTEX PHARMACEUTICALS INCORPORATED	-3.00%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.85%	96.29B	B+
ARGENX SE	+2.13%	22.18B	B
BIONTECH SE	-15.56%	21.2B	B+
GENMAB A/S	-9.21%	18.31B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.38B	A-
BEIGENE, LTD.	-15.51%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+5.15%	13.97B	C+
SAREPTA THERAPEUTICS, INC.	+32.62%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes